Swiss drugmaker Novartis on July 29 announced its combo sacubitril/valsartan drug Entresto “narrowly missed” its primary endpoint in the Phase III PARAGON-HF study, throwing into question the future of a blockbuster drug.

A study published July 17 in the Journal of the American College of Cardiology has revealed a strong link between cancer and takotsubo cardiomyopathy, or “broken heart syndrome.”

Methamphetamine abuse is on the rise among veterans with concomitant heart failure, according to a recent analysis published in the American Journal of Cardiology. 

Researchers in Italy are developing “smart,” photo-responsive materials they hope will replicate the mechanical properties of a human heart in an artificial format, Cosmos Magazine reported July 12.

The Center to Advance Palliative Care suggests steps cardiologists can take to ensure ongoing identification and management of remediable sources of suffering and distress in heart failure patients.

The combination heart failure drug sacubitril/valsartan is well-covered under Medicare Part D plans, according to a recent analysis, but patient access to the medication remains limited by steep out-of-pocket costs than can exceed $1,600 annually.

A large-scale study of people living with HIV has linked the immune deficiency to an increased risk of CVD, in particular heart failure and stroke.

Heart patients of a lower socioeconomic status are far more likely to participate in cardiac rehabilitation if they receive financial incentives to attend sessions, according to a study published in the July 1 edition of JACC: Heart Failure.